Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-07-21
1996-03-12
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 45, 536 276, 536 2714, 536 2722, 536 273, A61K 3170
Patent
active
054986052
ABSTRACT:
The adenosine derivatives which contain a sulfohydrocarbon substituent, as depicted in the formula: ##STR1## wherein at least one of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 is a sulfohydrocarbon radical and W is --OCH.sub.2 --, --NHCH.sub.2 --, --SCH.sub.2 --, or --NH(C.dbd.O)--. Methods of preparing such compounds, as well as methods of using such compounds to treat ischemia or hypoxia in mammals and pharmaceutical compositions containing such compounds as the active ingredients, are also described.
REFERENCES:
patent: 3388115 (1968-06-01), Alburn et al.
patent: 3471472 (1969-10-01), Thiel et al.
patent: 3502649 (1970-03-01), Thiel et al.
patent: 3506643 (1970-04-01), Thiel et al.
patent: 3622561 (1971-11-01), Robins et al.
patent: 3845035 (1974-10-01), Kampe et al.
patent: 4299832 (1981-11-01), Brown et al.
patent: 4479951 (1984-10-01), Klessing et al.
patent: 4853386 (1989-08-01), Friebe et al.
patent: 4892876 (1990-01-01), Hoshino et al.
patent: 4954504 (1990-09-01), Chen et al.
patent: 5063233 (1991-11-01), Chen et al.
Carrea et al., "Alkylation of adenine, adenosine, and NAD.sup.+ with 1,3-propanesultone. Synthesis of N.sup.6 -(3-sulfonatopropyl)-NAD.sup.+, a new NAD.sup.+ derivative with substantial coenzyme activity," Helvetica Chimica Acta, 71, 762-772 (1988).
Bruns, R., "Role of Adenosine in Energy Supply/Demand Balance," Nucleoside & Nucleotides, 10(5), 931-943 (1991).
Cheng, et al., "Relationship Between the Inhibition Constant (K.sub.1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I.sub.50) of an Enzymatic Reaction," Biochem. Parmacol., 22, 3099-3108 (1973).
Clemo, et al., "Antagonism of the Effects of Adenosine and Hypoxia on Atrioventricular Conduction Time by Two Novel Alkylxanthines: Correlation with Binding to Adenosine A.sub.1 Receptors," J. Pharmacol. Exp. Ther., 242, 478-484 (1987).
Daly, "Adenosine Receptors: Targets for Future Drugs," J. Med. Chem., 25, 197 (1982).
Durcan et al., "NECA-Induced Hypomotility in Mice: Evidence for a Predominantly Central Site of Action," Pharmacol. Biochem. Behav., 32, 487-490 (1989).
Eggstein, et al., "Triglycerides and Glycerol Determination after Alkaline Hydrolysis," Methods of Enzymatic Analysis, pp. 1825-1831 (1974).
Evans, et al., "An Adenosine Analogue, 2-Chloradenosine, Protects Against Long Term Development of Ischaemic Cell Loss in the Rat Hippocampus," Neurosc. Lett., 83, 287-292 (1987).
Jacobson, et al., "Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential," J. Med. Chem., 35, 407-422 (1992).
Jacobson, et al., "Functionalized Congeners of Adenosine: Preparation of Analogues with High Affinity for A.sub.1 -Adenosine Receptors," Journal Medical Chemistry, 28, 1341-1345 (1985).
Jarvis, et al., "[.sup.3 G]CGS 21680, A Selective A.sub.2 Adenosine Receptor Agonist Directly Labels A.sub.2 Receptors in Rat Brain," J. Pharm. Exp. Therap., 251, 888-893 (1989).
Lohse, et al, "2-Chloro-N.sup.6 -cyclopentyladenosine: a highly selective agonist at A.sub.1 adenosine receptors," Arch. Pharm., 337, 687-689 (1988).
Nikodijevic, et al., "Characterization of the locomotor depression produced by an A.sub.2 -selective adenosine agonist," FEBS Letters, 261, 67-70 (1990).
Nikodijevic, et al., "Behavioral Effects of A.sub.1 -and A.sub.2 -Selective Adenosine Agonists and Antagonists: Evidence for Synergims and Antagonism," J. Pharm. Exp. Therap., 259, 286-294 (1991).
Olsson, et al., "N.sup.6 -Substituted N-Alkyladenosine-5'-uronamides: Bifunctional Ligands Having Recognition Groups for A.sub.1 and A.sub.2 Adenosine Receptors," J. Med. Chem., 29(9), 1683-1689 (1986).
Pantely, et al., "Adenosine--Renewed Interest in an Old Drug," Circulation, 82, 1854 (1990).
Snyder, et al., "Adenosine Receptors and Behavioral Actions of Methylxanthines," Proc. Nat'l Acad. Sci. U.S.A., 78, 3260-3264.
van Galen, et al., "Adenosine Derivatives with N.sup.6 -Alkyl,-Alkylamine or -Alkyladenosine Substituents as probes for the A.sub.1 Receptor," FEBS Lett., 223(1), 197-201 (1987).
von Lubitz, et al., "Cerebral Ischemia in Gerbils: Postischemic Administration of Cyclohexyl Adenosine and 8-Sulfophenyl-theophylline," J. Mol. Neurosci., 2, 53-59 (1990).
J. Med. Chem., 35(22) 4143-9 (1992) Jacobson et al.
Jacobson Kenneth A.
Maillard Michel G.
Robinson Douglas W.
The United States of America as represented by the Department of
Wilson James O.
LandOfFree
Sulfo-derivatives of adenosine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfo-derivatives of adenosine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfo-derivatives of adenosine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100018